MPM Medical today announced a expansion of its U.S. manufacturing capabilities with the acquisition of a full collagen manufacturing platform and the associated FDA 510(k) clearance for surgical collagen devices.
This announcement follows last week's introduction of MPM Medical's Collagen At-Home Wound Care Kits and Proprietary Wound Care Portal.
Beginning January 1, 2026, the company's collagen production will operate out of MPM Medical's 100,000-square-foot FDA-registered facility in Mesquite, Texas. The expansion includes advanced collagen processing technology, USP-grade compounding, and several high-capacity lyophilizers.
All collagen is U.S.-made, non-hydrolyzed, and derived from Type I bovine sources without added chemicals or chemical crosslinking.
"By bringing surgical and wound care collagen manufacturing fully in-house, we can innovate faster, scale production responsibly, and provide our partners with reliable, FDA-cleared solutions," said MPM Medical CEO Sudheer Kancherla in a statement. "This is a major milestone not just for MPM Medical, but for every clinician and company seeking dependable, American-made collagen."
